Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. Siegel DS et al. Blood Cancer J. 2014 Feb 21;4:e182. doi: 10.1038/bcj.2014.1. Daratumumab granted breakthrough drug status. Laubach JP et al. Expert Opin Investig Drugs. 2014 Feb 20. [Epub ahead of print]. Anti-CD40-mediated cancer immunotherapy: an update of recent and…
Novel afucosylated anti-B cell maturation antigen-monomethyl auristatin F antibody-drug conjugate (GSK2857916) induces potent and selective anti-multiple myeloma activity. Tai YT et al. Blood. 2014 Feb 25. [Epub ahead of print]. Bone marrow mast cell density correlates with serum levels of VEGF and CXC chemokines ENA-78 and GRO-α in multiple myeloma. Pappa CA et al. Tumour…
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Palumbo A et al. Lancet Oncol. 2014 Feb 10. pii: S1470-2045(13)70609-0. doi: 10.1016/S1470-2045(13)70609-0. [Epub ahead of print]. Lenalidomide and second malignancies in myeloma patients. Pratt G. Lancet Oncol. 2014 Feb 10. pii: S1470-2045(14)70001-4. doi: 10.1016/S1470-2045(14)70001-4. [Epub ahead of print].…
Subcutaneous Bortezomib incorporated into the Bortezomib-Thalidomide-Dexamethasone regimen as part of frontline therapy in the context of autologous stem-cell transplantation for multiple myeloma.
Lok A et al. Haematologica. 2014 Feb 14. [Epub ahead of print]
Long-term outcome of monoclonal (type 1) cryoglobulinemia.
Néel A et al. Am J Hematol. 2014 Feb;89(2):156-61. doi: 10.1002/ajh.23608.
Is it time for preemptive drug treatment of asymptomatic (smoldering) multiple myeloma?
Fawole A et al. Leuk Lymphoma. 2014 Feb 25. [Epub ahead of print].
International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. Palumbo A et al. J Clin Oncol. 2014 Jan 13. [Epub ahead of print]. Initial treatment of transplant-eligible patients in multiple myeloma. Rosiñol L et al. Expert Rev Hematol. 2014 Jan…
Molecular methods for detection of minimal residual disease following transplantation in lymphoid and plasma cell disorders. Corradini P et al. Methods Mol Biol. 2014;1109:209-37. doi: 10.1007/978-1-4614-9437-9_12. Clinical Contribution of PET/CT in Myeloma: From the Perspective of a Radiologist. Nakamoto Y. Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):10-1. doi: 10.1016/j.clml.2013.12.005. Epub 2013 Dec 21. Prognostic value of…
Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy.Berenson JR et al. Leukemia. 2014 Jan 16. doi: 10.1038/leu.2014.27. [Epub ahead of print].Immunotherapy for multiple myeloma.Rosenblatt J et al. Expert Rev Hematol. 2014 Jan 13. [Epub ahead of print].Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin…
Autologous Stem Cell Transplantation for POEMS Syndrome. Nakaseko C.Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):21-3. doi: 10.1016/j.clml.2013.12.009. Epub 2013 Dec 22. Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome. Patel K et al. Bone Marrow Transplant. 2014 Jan 13. doi: 10.1038/bmt.2013.209. [Epub ahead of print]. Can autologous bone marrow transplantation improve systolic function…
Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematological Cancers. Garcia PD et al. Clin Cancer Res. 2014 Jan 28. [Epub ahead of print]. Mechanisms and consequences of constitutive NF-κB activation in B-cell lymphoid malignancies. Nagel D et al. Oncogene. 2014 Jan 27. doi: 10.1038/onc.2013.565. [Epub ahead of print]. Cyclin D1 Amplification in Multiple…